<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00740857</url>
  </required_header>
  <id_info>
    <org_study_id>PV-08-24</org_study_id>
    <nct_id>NCT00740857</nct_id>
  </id_info>
  <brief_title>Study Comparing the Efficacy of Two Ibuprofen Formulations</brief_title>
  <official_title>A Study Comparing the Efficacy of Two Ibuprofen Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of healthy volunteers to compare how quickly different ibuprofen products
      relieve dental pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Meaningful Pain Relief</measure>
    <time_frame>0-6 hours</time_frame>
    <description>Subjects evaluated the time to &quot;First Perceptible&quot; Relief by depressing a stopwatch at the moment they first began to experience &quot;perceptible&quot; relief and the time to &quot;Meaningful&quot; Relief by depressing a second stopwatch at the moment they first began to experience &quot;meaningful&quot; relief. These times were recorded up to 6 hrs after dosing. Range: up to 6 hrs, a lower number is better.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference (PID) Scores at Each Individual Time Points</measure>
    <time_frame>0-6 hours</time_frame>
    <description>PID is based on the 4-point categorical pain severity score ranging from 0 (none) to 3 (severe), this value was derived by subtracting the score at each post-dosing time point from the baseline score, so that a higher positive value is indicative of greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PR) Scores at Individual Time Points</measure>
    <time_frame>0-6 hours</time_frame>
    <description>Response to the question &quot;How much pain do you have from your starting pain?&quot; was recorded on a 5-point categorical pain relief scale (None (0), A Little (1), Some (2), A Lot (3) or Complete (4)) at designated time points after study medication was taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-weighted Sum of Pain Relief + Pain Intensity Difference (SPRID) From 0-2 Hours and 0-6 Hours</measure>
    <time_frame>0-2 and 0-6 hours</time_frame>
    <description>SPRID is a derived endpoint from the pain relief and pain intensity difference scores from 0-2 hours and 0-6 hours. PRID=PID+Pain Relief Score. SPRID-02 range: -2 (worst) to 14 (best); SPRID 06 range: -6 (worst) to 42 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief Combined With Pain Intensity Difference (PRID) Scores at Individual Time Points</measure>
    <time_frame>0-6 hours</time_frame>
    <description>PRID (PRID=PID+PR) is a derived endpoint from the pain relief and pain intensity difference scores at each time point. Range: -1 (worst) to 7 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-weighted Sum of Pain Intensity Difference (SPID) From 0-2 Hours and 0-6 Hours</measure>
    <time_frame>0-2 and 0-6 hours</time_frame>
    <description>SPID is a derived endpoint from the pain intensity difference scores from 0-2 hours and 0-6 hours. Range: -2 (worst) to 6 (best); -6 (worst) to 18 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-weighted Sum of Pain Relief Scores (TOTPAR) From 0-2 Hours and 0-6 Hours</measure>
    <time_frame>0-2 and 0-6 hours</time_frame>
    <description>TOTPAR is a derived endpoint from the pain relief scores from 0-2 hours and 0-6 hours. Range: 0 (worst) - 8 (best); 0 (worst) - 24 (best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Perceptible Relief</measure>
    <time_frame>0-6 hours</time_frame>
    <description>The elapsed time from dosing until the patient indicated first perceptible relief, provided the subject also indicated achieving meaningful relief.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">211</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>2 placebo gels capsules delivered as a single dose.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibuprofen Formulation 1</intervention_name>
    <description>2 marketed ibuprofen gels</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibuprofen Formulation 2</intervention_name>
    <description>2 marketed ibuprofen gels</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Outpatients with post-operative pain following surgical extraction of third molars,

          -  examined by the attending dentist or physician and medically cleared to participate in
             the study,

          -  in general good health and have no contraindications to the study or rescue
             medication.

        Exclusions criteria:

          -  any serious medical condition,

          -  acute localized dental infection at the time of surgery ,

          -  females who are pregnant, lactating, of child-bearing potential, or post-menopausal
             for less than 2 years and not using a medically approved method of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2008</study_first_submitted>
  <study_first_submitted_qc>August 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2008</study_first_posted>
  <results_first_submitted>October 30, 2009</results_first_submitted>
  <results_first_submitted_qc>July 15, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 12, 2010</results_first_posted>
  <last_update_submitted>June 1, 2011</last_update_submitted>
  <last_update_submitted_qc>June 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Wyeth (Registry Contact: Clinical Trial Registry Specialist)</name_title>
    <organization>Wyeth</organization>
  </responsible_party>
  <keyword>Dental pain analgesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited in the United States from August 2008 to October 2008.</recruitment_details>
      <pre_assignment_details>During the screening period, the Investigator or his/her designee examined each subject and completed a checklist of the inclusion/exclusion criteria in order to determine the patient’s eligibility. Surgery occurred within 14 days of the screening visit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>2 placebo gel capsules delivered as a single dose up to 5 hours after surgery</description>
        </group>
        <group group_id="P2">
          <title>Ibuprofen Formulation 1</title>
          <description>2 marketed ibuprofen 200 mg liquid gels up to 5 hours after surgery</description>
        </group>
        <group group_id="P3">
          <title>Ibuprofen Formulation 2</title>
          <description>2 marketed ibuprofen 200 mg soft gels up to 5 hours after surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>2 placebo gel capsules delivered as a single dose up to 5 hours after surgery</description>
        </group>
        <group group_id="B2">
          <title>Ibuprofen Formulation 1</title>
          <description>2 marketed ibuprofen 200 mg liquid gels up to 5 hours after surgery</description>
        </group>
        <group group_id="B3">
          <title>Ibuprofen Formulation 2</title>
          <description>2 marketed ibuprofen 200 mg soft gels up to 5 hours after surgery</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="88"/>
            <count group_id="B3" value="90"/>
            <count group_id="B4" value="211"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.8" spread="2.7"/>
                    <measurement group_id="B2" value="18.5" spread="2.5"/>
                    <measurement group_id="B3" value="19.0" spread="3.0"/>
                    <measurement group_id="B4" value="18.8" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Meaningful Pain Relief</title>
        <description>Subjects evaluated the time to “First Perceptible” Relief by depressing a stopwatch at the moment they first began to experience “perceptible” relief and the time to “Meaningful” Relief by depressing a second stopwatch at the moment they first began to experience “meaningful” relief. These times were recorded up to 6 hrs after dosing. Range: up to 6 hrs, a lower number is better.</description>
        <time_frame>0-6 hours</time_frame>
        <population>All randomized patients who were dosed with study product, indicated a baseline score of at least 2 out of 4 on the Categorical Pain Severity Rating Scale and confirmed a pain assessment of at least 50 mm out of 100 mm on the Visual Analog Scale (VAS). Median pain relief was not reached for the placebo participants within 360 minutes.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>2 placebo gel capsules delivered as a single dose up to 5 hours after surgery</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Formulation 1</title>
            <description>2 marketed ibuprofen 200 mg liquid gels up to 5 hours after surgery</description>
          </group>
          <group group_id="O3">
            <title>Ibuprofen Formulation 2</title>
            <description>2 marketed ibuprofen 200 mg soft gels up to 5 hours after surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Meaningful Pain Relief</title>
          <description>Subjects evaluated the time to “First Perceptible” Relief by depressing a stopwatch at the moment they first began to experience “perceptible” relief and the time to “Meaningful” Relief by depressing a second stopwatch at the moment they first began to experience “meaningful” relief. These times were recorded up to 6 hrs after dosing. Range: up to 6 hrs, a lower number is better.</description>
          <population>All randomized patients who were dosed with study product, indicated a baseline score of at least 2 out of 4 on the Categorical Pain Severity Rating Scale and confirmed a pain assessment of at least 50 mm out of 100 mm on the Visual Analog Scale (VAS). Median pain relief was not reached for the placebo participants within 360 minutes.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="45.4" lower_limit="41.5" upper_limit="53.5"/>
                    <measurement group_id="O3" value="63.6" lower_limit="58.6" upper_limit="84.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Proportional hazards model</method>
            <method_desc>Adjusted with treatment, baseline Pain Severity Rating (PSR), and gender terms.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Proportional hazards model</method>
            <method_desc>Adjusted with treatment, baseline Pain Severity Rating (PSR), and gender terms.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Proportional hazards model</method>
            <method_desc>Adjusted with treatment, baseline Pain Severity Rating (PSR), and gender terms.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference (PID) Scores at Each Individual Time Points</title>
        <description>PID is based on the 4-point categorical pain severity score ranging from 0 (none) to 3 (severe), this value was derived by subtracting the score at each post-dosing time point from the baseline score, so that a higher positive value is indicative of greater improvement.</description>
        <time_frame>0-6 hours</time_frame>
        <population>All randomized patients who were dosed with study product, indicated a baseline score of at least 2 out of 4 on the Categorical Pain Severity Rating Scale and confirmed a pain assessment of at least 50 mm out of 100 mm on the Visual Analog Scale (VAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>2 placebo gel capsules delivered as a single dose up to 5 hours after surgery</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Formulation 1</title>
            <description>2 marketed ibuprofen 200 mg liquid gels up to 5 hours after surgery</description>
          </group>
          <group group_id="O3">
            <title>Ibuprofen Formulation 2</title>
            <description>2 marketed ibuprofen 200 mg soft gels up to 5 hours after surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference (PID) Scores at Each Individual Time Points</title>
          <description>PID is based on the 4-point categorical pain severity score ranging from 0 (none) to 3 (severe), this value was derived by subtracting the score at each post-dosing time point from the baseline score, so that a higher positive value is indicative of greater improvement.</description>
          <population>All randomized patients who were dosed with study product, indicated a baseline score of at least 2 out of 4 on the Categorical Pain Severity Rating Scale and confirmed a pain assessment of at least 50 mm out of 100 mm on the Visual Analog Scale (VAS).</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.4"/>
                    <measurement group_id="O2" value="0.2" spread="0.5"/>
                    <measurement group_id="O3" value="0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.5"/>
                    <measurement group_id="O2" value="0.8" spread="0.8"/>
                    <measurement group_id="O3" value="0.5" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.7"/>
                    <measurement group_id="O2" value="1.3" spread="0.8"/>
                    <measurement group_id="O3" value="0.9" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.7"/>
                    <measurement group_id="O2" value="1.6" spread="0.9"/>
                    <measurement group_id="O3" value="1.2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.8"/>
                    <measurement group_id="O2" value="1.8" spread="0.9"/>
                    <measurement group_id="O3" value="1.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.8"/>
                    <measurement group_id="O2" value="1.8" spread="0.9"/>
                    <measurement group_id="O3" value="1.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.0"/>
                    <measurement group_id="O2" value="1.7" spread="1.0"/>
                    <measurement group_id="O3" value="1.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>240 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.2"/>
                    <measurement group_id="O2" value="1.5" spread="1.0"/>
                    <measurement group_id="O3" value="1.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>300 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.0"/>
                    <measurement group_id="O2" value="1.4" spread="1.0"/>
                    <measurement group_id="O3" value="1.4" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>360 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.0"/>
                    <measurement group_id="O2" value="1.2" spread="1.0"/>
                    <measurement group_id="O3" value="1.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>15 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.118</p_value>
            <method>ANOVA</method>
            <method_desc>With treatment, baseline Pain Severity Rating (PSR), and gender terms.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The 30, 45, 60....</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>With treatment, baseline Pain Severity Rating (PSR), and gender terms.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief (PR) Scores at Individual Time Points</title>
        <description>Response to the question &quot;How much pain do you have from your starting pain?&quot; was recorded on a 5-point categorical pain relief scale (None (0), A Little (1), Some (2), A Lot (3) or Complete (4)) at designated time points after study medication was taken.</description>
        <time_frame>0-6 hours</time_frame>
        <population>All randomized patients who were dosed with study product, indicated a baseline score of at least 2 out of 4 on the Categorical Pain Severity Rating Scale and confirmed a pain assessment of at least 50 mm out of 100 mm on the Visual Analog Scale (VAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>2 placebo gel capsules delivered as a single dose up to 5 hours after surgery</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Formulation 1</title>
            <description>2 marketed ibuprofen 200 mg liquid gels up to 5 hours after surgery</description>
          </group>
          <group group_id="O3">
            <title>Ibuprofen Formulation 2</title>
            <description>2 marketed ibuprofen 200 mg soft gels up to 5 hours after surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PR) Scores at Individual Time Points</title>
          <description>Response to the question &quot;How much pain do you have from your starting pain?&quot; was recorded on a 5-point categorical pain relief scale (None (0), A Little (1), Some (2), A Lot (3) or Complete (4)) at designated time points after study medication was taken.</description>
          <population>All randomized patients who were dosed with study product, indicated a baseline score of at least 2 out of 4 on the Categorical Pain Severity Rating Scale and confirmed a pain assessment of at least 50 mm out of 100 mm on the Visual Analog Scale (VAS).</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.5"/>
                    <measurement group_id="O2" value="0.5" spread="0.8"/>
                    <measurement group_id="O3" value="0.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.8"/>
                    <measurement group_id="O2" value="1.6" spread="1.1"/>
                    <measurement group_id="O3" value="1.0" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.0"/>
                    <measurement group_id="O2" value="2.4" spread="1.1"/>
                    <measurement group_id="O3" value="1.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.1"/>
                    <measurement group_id="O2" value="2.9" spread="1.0"/>
                    <measurement group_id="O3" value="2.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.1"/>
                    <measurement group_id="O2" value="3.2" spread="1.0"/>
                    <measurement group_id="O3" value="2.7" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.2"/>
                    <measurement group_id="O2" value="3.2" spread="1.0"/>
                    <measurement group_id="O3" value="2.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.4"/>
                    <measurement group_id="O2" value="3.0" spread="1.1"/>
                    <measurement group_id="O3" value="2.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>240 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.6"/>
                    <measurement group_id="O2" value="2.7" spread="1.2"/>
                    <measurement group_id="O3" value="2.7" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>300 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.2"/>
                    <measurement group_id="O2" value="2.5" spread="1.4"/>
                    <measurement group_id="O3" value="2.6" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>360 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.3"/>
                    <measurement group_id="O2" value="2.2" spread="1.3"/>
                    <measurement group_id="O3" value="2.6" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>15 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>ANOVA</method>
            <method_desc>With treatment, baseline Pain Severity Rating (PSR), and gender terms.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The 30, 45, 60, 90, 120, 180, 240, 300 and 360 minute individual time points all have the same P-value score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>With treatment, baseline Pain Severity Rating (PSR), and gender terms.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-weighted Sum of Pain Relief + Pain Intensity Difference (SPRID) From 0-2 Hours and 0-6 Hours</title>
        <description>SPRID is a derived endpoint from the pain relief and pain intensity difference scores from 0-2 hours and 0-6 hours. PRID=PID+Pain Relief Score. SPRID-02 range: -2 (worst) to 14 (best); SPRID 06 range: -6 (worst) to 42 (best).</description>
        <time_frame>0-2 and 0-6 hours</time_frame>
        <population>All randomized patients who were dosed with study product, indicated a baseline score of at least 2 out of 4 on the Categorical Pain Severity Rating Scale and confirmed a pain assessment of at least 50 mm out of 100 mm on the Visual Analog Scale (VAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>2 placebo gel capsules delivered as a single dose up to 5 hours after surgery</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Formulation 1</title>
            <description>2 marketed ibuprofen 200 mg liquid gels up to 5 hours after surgery</description>
          </group>
          <group group_id="O3">
            <title>Ibuprofen Formulation 2</title>
            <description>2 marketed ibuprofen 200 mg soft gels up to 5 hours after surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Time-weighted Sum of Pain Relief + Pain Intensity Difference (SPRID) From 0-2 Hours and 0-6 Hours</title>
          <description>SPRID is a derived endpoint from the pain relief and pain intensity difference scores from 0-2 hours and 0-6 hours. PRID=PID+Pain Relief Score. SPRID-02 range: -2 (worst) to 14 (best); SPRID 06 range: -6 (worst) to 42 (best).</description>
          <population>All randomized patients who were dosed with study product, indicated a baseline score of at least 2 out of 4 on the Categorical Pain Severity Rating Scale and confirmed a pain assessment of at least 50 mm out of 100 mm on the Visual Analog Scale (VAS).</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0-2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="2.9"/>
                    <measurement group_id="O2" value="7.8" spread="2.9"/>
                    <measurement group_id="O3" value="6.3" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0-6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="11.9"/>
                    <measurement group_id="O2" value="24.0" spread="10.1"/>
                    <measurement group_id="O3" value="23.0" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>With treatment, baseline Pain Severity Rating (PSR), and gender terms.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief Combined With Pain Intensity Difference (PRID) Scores at Individual Time Points</title>
        <description>PRID (PRID=PID+PR) is a derived endpoint from the pain relief and pain intensity difference scores at each time point. Range: -1 (worst) to 7 (best).</description>
        <time_frame>0-6 hours</time_frame>
        <population>All randomized patients who were dosed with study product, indicated a baseline score of at least 2 out of 4 on the Categorical Pain Severity Rating Scale and confirmed a pain assessment of at least 50 mm out of 100 mm on the Visual Analog Scale (VAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>2 placebo gel capsules delivered as a single dose up to 5 hours after surgery</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Formulation 1</title>
            <description>2 marketed ibuprofen 200 mg liquid gels up to 5 hours after surgery</description>
          </group>
          <group group_id="O3">
            <title>Ibuprofen Formulation 2</title>
            <description>2 marketed ibuprofen 200 mg soft gels up to 5 hours after surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief Combined With Pain Intensity Difference (PRID) Scores at Individual Time Points</title>
          <description>PRID (PRID=PID+PR) is a derived endpoint from the pain relief and pain intensity difference scores at each time point. Range: -1 (worst) to 7 (best).</description>
          <population>All randomized patients who were dosed with study product, indicated a baseline score of at least 2 out of 4 on the Categorical Pain Severity Rating Scale and confirmed a pain assessment of at least 50 mm out of 100 mm on the Visual Analog Scale (VAS).</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.8"/>
                    <measurement group_id="O2" value="0.7" spread="1.2"/>
                    <measurement group_id="O3" value="0.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.2"/>
                    <measurement group_id="O2" value="2.4" spread="1.8"/>
                    <measurement group_id="O3" value="1.4" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.6"/>
                    <measurement group_id="O2" value="3.6" spread="1.8"/>
                    <measurement group_id="O3" value="2.5" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.8"/>
                    <measurement group_id="O2" value="4.5" spread="1.8"/>
                    <measurement group_id="O3" value="3.3" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.9"/>
                    <measurement group_id="O2" value="5.0" spread="1.7"/>
                    <measurement group_id="O3" value="4.2" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="2.0"/>
                    <measurement group_id="O2" value="5.0" spread="1.8"/>
                    <measurement group_id="O3" value="4.6" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="2.4"/>
                    <measurement group_id="O2" value="4.7" spread="2.0"/>
                    <measurement group_id="O3" value="4.6" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>240 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.7"/>
                    <measurement group_id="O2" value="4.2" spread="2.1"/>
                    <measurement group_id="O3" value="4.2" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>300 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="2.1"/>
                    <measurement group_id="O2" value="3.9" spread="2.3"/>
                    <measurement group_id="O3" value="4.0" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>360 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="2.2"/>
                    <measurement group_id="O2" value="3.4" spread="2.3"/>
                    <measurement group_id="O3" value="3.9" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>15 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <method>ANOVA</method>
            <method_desc>Adjusted with treatment, baseline Pain Severity Rating (PSR), and gender terms.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The 30, 45, 60, 90, 120, 180, 240, 300 and 360 minute individual time points all have the same P-value score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Adjusted with treatment, baseline Pain Severity Rating (PSR), and gender terms.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-weighted Sum of Pain Intensity Difference (SPID) From 0-2 Hours and 0-6 Hours</title>
        <description>SPID is a derived endpoint from the pain intensity difference scores from 0-2 hours and 0-6 hours. Range: -2 (worst) to 6 (best); -6 (worst) to 18 (best).</description>
        <time_frame>0-2 and 0-6 hours</time_frame>
        <population>All randomized patients who were dosed with study product, indicated a baseline score of at least 2 out of 4 on the Categorical Pain Severity Rating Scale and confirmed a pain assessment of at least 50 mm out of 100 mm on the Visual Analog Scale (VAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>2 placebo gel capsules delivered as a single dose up to 5 hours after surgery</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Formulation 1</title>
            <description>2 marketed ibuprofen 200 mg liquid gels up to 5 hours after surgery</description>
          </group>
          <group group_id="O3">
            <title>Ibuprofen Formulation 2</title>
            <description>2 marketed ibuprofen 200 mg soft gels up to 5 hours after surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Time-weighted Sum of Pain Intensity Difference (SPID) From 0-2 Hours and 0-6 Hours</title>
          <description>SPID is a derived endpoint from the pain intensity difference scores from 0-2 hours and 0-6 hours. Range: -2 (worst) to 6 (best); -6 (worst) to 18 (best).</description>
          <population>All randomized patients who were dosed with study product, indicated a baseline score of at least 2 out of 4 on the Categorical Pain Severity Rating Scale and confirmed a pain assessment of at least 50 mm out of 100 mm on the Visual Analog Scale (VAS).</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0-2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.2"/>
                    <measurement group_id="O2" value="2.8" spread="1.4"/>
                    <measurement group_id="O3" value="2.2" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0-6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="5.2"/>
                    <measurement group_id="O2" value="8.6" spread="4.8"/>
                    <measurement group_id="O3" value="8.1" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Adjusted with treatment, baseline Pain Severity Rating (PSR), and gender terms.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-weighted Sum of Pain Relief Scores (TOTPAR) From 0-2 Hours and 0-6 Hours</title>
        <description>TOTPAR is a derived endpoint from the pain relief scores from 0-2 hours and 0-6 hours. Range: 0 (worst) - 8 (best); 0 (worst) - 24 (best)</description>
        <time_frame>0-2 and 0-6 hours</time_frame>
        <population>All randomized patients who were dosed with study product, indicated a baseline score of at least 2 out of 4 on the Categorical Pain Severity Rating Scale and confirmed a pain assessment of at least 50 mm out of 100 mm on the Visual Analog Scale (VAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>2 placebo gel capsules delivered as a single dose up to 5 hours after surgery</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Formulation 1</title>
            <description>2 marketed ibuprofen 200 mg liquid gels up to 5 hours after surgery</description>
          </group>
          <group group_id="O3">
            <title>Ibuprofen Formulation 2</title>
            <description>2 marketed ibuprofen 200 mg soft gels up to 5 hours after surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Time-weighted Sum of Pain Relief Scores (TOTPAR) From 0-2 Hours and 0-6 Hours</title>
          <description>TOTPAR is a derived endpoint from the pain relief scores from 0-2 hours and 0-6 hours. Range: 0 (worst) - 8 (best); 0 (worst) - 24 (best)</description>
          <population>All randomized patients who were dosed with study product, indicated a baseline score of at least 2 out of 4 on the Categorical Pain Severity Rating Scale and confirmed a pain assessment of at least 50 mm out of 100 mm on the Visual Analog Scale (VAS).</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0-2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.8"/>
                    <measurement group_id="O2" value="5.0" spread="1.7"/>
                    <measurement group_id="O3" value="4.1" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0-6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="7.1"/>
                    <measurement group_id="O2" value="15.4" spread="5.7"/>
                    <measurement group_id="O3" value="14.9" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Adjusted with treatment, baseline Pain Severity Rating (PSR), and gender terms.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Perceptible Relief</title>
        <description>The elapsed time from dosing until the patient indicated first perceptible relief, provided the subject also indicated achieving meaningful relief.</description>
        <time_frame>0-6 hours</time_frame>
        <population>All randomized patients who were dosed with study product, indicated a baseline score of at least 2 out of 4 on the Categorical Pain Severity Rating Scale and confirmed a pain assessment of at least 50 mm out of 100 mm on the Visual Analog Scale (VAS). Median pain relief was not reached for the placebo participants within 360 minutes.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>2 placebo gel capsules delivered as a single dose up to 5 hours after surgery</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Formulation 1</title>
            <description>2 marketed ibuprofen 200 mg liquid gels up to 5 hours after surgery</description>
          </group>
          <group group_id="O3">
            <title>Ibuprofen Formulation 2</title>
            <description>2 marketed ibuprofen 200 mg soft gels up to 5 hours after surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Perceptible Relief</title>
          <description>The elapsed time from dosing until the patient indicated first perceptible relief, provided the subject also indicated achieving meaningful relief.</description>
          <population>All randomized patients who were dosed with study product, indicated a baseline score of at least 2 out of 4 on the Categorical Pain Severity Rating Scale and confirmed a pain assessment of at least 50 mm out of 100 mm on the Visual Analog Scale (VAS). Median pain relief was not reached for the placebo participants within 360 minutes.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="23.7" lower_limit="20.6" upper_limit="26.6"/>
                    <measurement group_id="O3" value="28.6" lower_limit="25.9" upper_limit="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>proportional hazards model</method>
            <method_desc>Adjusted with treatment, baseline Pain Severity Rating (PSR), and gender terms.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>2 placebo gel capsules delivered as a single dose up to 5 hours after surgery</description>
        </group>
        <group group_id="E2">
          <title>Ibuprofen Formulation 1</title>
          <description>2 marketed ibuprofen 200 mg liquid gels up to 5 hours after surgery</description>
        </group>
        <group group_id="E3">
          <title>Ibuprofen Formulation 2</title>
          <description>2 marketed ibuprofen 200 mg soft gels up to 5 hours after surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Dry socket</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI agreed to allow the sponsor 30 days to review and approve abstracts and 60 days to review and approve manuscripts prior to submission to protect against disclosure of confidential information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>U. S. Contact Center</name_or_title>
      <organization>Wyeth</organization>
      <email>clintrialresults@wyeth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

